Regeneron reinforced its commitment to environmental sustainability this week by sharing an overview of past green accomplishments and new sustainability commitments.
Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA
Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015
We have an extensive pipeline of investigational product candidates that are progressing through all stages of human clinical trials. Our product candidates address many serious medical conditions including cancer, eye diseases, inflammatory diseases, pain, cardiovascular diseases, and allergic conditions.
We are committed to
to science, to our people, and
above all, to the patients
whom we serve.
Quality Compliance Specialist